As for drug sensitivity, the low-risk group was more sensitive to multiple inhibitors of the PI3K/AKT/mTOR pathway, such as OSI-027, which not only enhanced immunotherapeutic effects [38] but also blocked the progression of HNSCC [39]. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.